{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:20:29Z","timestamp":1791645629898,"version":"4.3.4"},"reference-count":35,"publisher":"American Academy of Pediatrics (AAP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND<\/jats:title>\n                  <jats:p>At our institution, empirical vancomycin is overused in children with suspected bacterial community-acquired infections (CAIs) admitted to the PICU because of high community rates of methicillin-resistant Staphylococcus aureus (MRSA). Our goal was to reduce unnecessary vancomycin use for CAIs in the PICU.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS<\/jats:title>\n                  <jats:p>Empirical PICU vancomycin indications for suspected CAIs were developed by using epidemiological risk factors for MRSA. We aimed to reduce empirical PICU vancomycin use in CAIs by 30%. After retrospectively testing, the indications were implemented and monthly PICU empirical vancomycin use during baseline (May 2017\u2013April 2018) and postintervention (May 2018\u2013July 2019) periods. Education was provided to PICU providers, vancomycin indications were posted, and the antibiotic order set was revised. Statistical process control methods tracked improvement over time. Proven S aureus infections for which vancomycin was not empirically prescribed and linezolid or clindamycin use were balancing measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>We identified 1620 PICU patients with suspected bacterial CAIs. Empirical vancomycin decreased from a baseline of 73% to 45%, a 38% relative reduction. No patient not prescribed empirical vancomycin later required the addition of vancomycin or other MRSA-targeted antibiotics. There was no change in nephrotoxicity or in the balancing measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>Development of clear and concise recommendations, combined with clinician education and decision support via an order set, was an effective and safe strategy to reduce PICU vancomycin use. Retrospective validation of the recommendations with local data were key to obtaining PICU clinician buy in.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2020-009142","type":"journal-article","created":{"date-parts":[[2021,8,27]],"date-time":"2021-08-27T08:25:24Z","timestamp":1630052724000},"source":"Crossref","is-referenced-by-count":6,"title":["Empiric Vancomycin Reduction in a Pediatric Intensive Care Unit"],"prefix":"10.1542","volume":"148","author":[{"given":"Mariana M.","family":"Lanata","sequence":"first","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Diaz","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaina M.","family":"Hecht","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aspasia","family":"Katragkou","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Gallup","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don A.","family":"Buckingham","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Tansmore","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Sargel","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua R.","family":"Watson","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Karsies","sequence":"additional","affiliation":[{"name":"Nationwide Children\u2019s Hospital, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2021,9,1]]},"reference":[{"key":"2022010419515758000_B1","volume-title":"Global Action Plan on Antimicrobial Resistance","author":"World Health Organization","year":"2016"},{"key":"2022010419515758000_B2","unstructured":"Centers for Disease Control and Prevention\n          . Antibiotic resistance threats in the United States, 2019. 2019. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/threats-report\/2019-ar-threats-report-508.pdf. Accessed October 30, 2020"},{"key":"2022010419515758000_B3","unstructured":"Centers for Disease Control and Prevention\n          . Antibiotic resistance threats in the United States, 2013. 2013. Available at: https:\/\/www.cdc.gov\/drugresistance\/pdf\/ar-threats-2013-508.pdf. Accessed June 21, 2020"},{"issue":"4","key":"2022010419515758000_B4","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00020-18","article-title":"Methicillin-resistant Staphylococcus aureus: molecular characterization, evolution, and epidemiology","volume":"31","author":"Lakhundi","year":"2018","journal-title":"Clin Microbiol Rev"},{"issue":"8","key":"2022010419515758000_B5","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1001\/jama.279.8.593","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk","volume":"279","author":"Herold","year":"1998","journal-title":"JAMA"},{"issue":"4","key":"2022010419515758000_B6","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1086\/520437","article-title":"Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors","volume":"29","author":"Gorak","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2022010419515758000_B7","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"2022010419515758000_B8","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2022010419515758000_B9","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"issue":"6","key":"2022010419515758000_B10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/j.1469-0691.2009.02934.x","article-title":"Case-control study to identify factors associated with mortality among patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"16","author":"Marchaim","year":"2010","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"2022010419515758000_B11","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1093\/jac\/dkq373","article-title":"Importance of appropriate empirical antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia","volume":"65","author":"Paul","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"2022010419515758000_B12","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"issue":"5","key":"2022010419515758000_B13","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijantimicag.2017.01.008","article-title":"Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among hospitalised paediatric patients: a systematic review and meta-analysis","volume":"49","author":"Flokas","year":"2017","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"2022010419515758000_B14","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1111\/chd.12187","article-title":"Vancomycin-associated acute kidney injury in pediatric cardiac intensive care patients","volume":"10","author":"Moffett","year":"2015","journal-title":"Congenit Heart Dis"},{"issue":"7","key":"2022010419515758000_B15","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1097\/INF.0000000000001882","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","volume":"37","author":"Fiorito","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"2022010419515758000_B16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.bcp.2016.09.007","article-title":"Antibiotic use and microbiome function","volume":"134","author":"Ferrer","year":"2017","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"2022010419515758000_B17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0196-6553(95)90104-3","article-title":"Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC)","volume":"23","year":"1995","journal-title":"Am J Infect Control"},{"issue":"4","key":"2022010419515758000_B18","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/2279-042X.192453","article-title":"A new approach to Vancomycin utilization evaluation: a cross-sectional study in intensive care unit","volume":"5","author":"Mahmoodian","year":"2016","journal-title":"J Res Pharm Pract"},{"issue":"11","key":"2022010419515758000_B19","doi-asserted-by":"crossref","first-page":"780","DOI":"10.2307\/30141327","article-title":"Evaluation of vancomycin use in a pediatric teaching hospital based on CDC criteria","volume":"18","author":"Logsdon","year":"1997","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"2022010419515758000_B20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/664761","article-title":"Rates and appropriateness of antimicrobial prescribing at an academic children\u2019s hospital, 2007-2010","volume":"33","author":"Levy","year":"2012","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"10","key":"2022010419515758000_B21","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1513\/AnnalsATS.201408-389OC","article-title":"An empiric antibiotic protocol using risk stratification improves antibiotic selection and timing in critically ill children","volume":"11","author":"Karsies","year":"2014","journal-title":"Ann Am Thorac Soc"},{"issue":"5","key":"2022010419515758000_B22","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/irv.12398","article-title":"The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis","volume":"10","author":"Klein","year":"2016","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"2022010419515758000_B23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jiac.2016.02.012","article-title":"Empirical therapy in methicillin-resistant Staphylococcus aureus infections: an up-to-date approach","volume":"22","author":"VanEperen","year":"2016","journal-title":"J Infect Chemother"},{"issue":"12","key":"2022010419515758000_B24","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/bmjqs-2015-004411","article-title":"SQUIRE 2.0 (Standards for QUality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process","volume":"25","author":"Ogrinc","year":"2016","journal-title":"BMJ Qual Saf"},{"issue":"8","key":"2022010419515758000_B25","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/INF.0b013e3181d683f8","article-title":"Impact of antimicrobial stewardship program on vancomycin use in a pediatric teaching hospital","volume":"29","author":"Di Pentima","year":"2010","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"2022010419515758000_B26","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1177\/0897190016635478","article-title":"Vancomycin use: room for improvement among hospitalized children","volume":"30","author":"Gillon","year":"2017","journal-title":"J Pharm Pract"},{"issue":"10","key":"2022010419515758000_B27","doi-asserted-by":"crossref","first-page":"e51","DOI":"10.1093\/cid\/ciw118","article-title":"Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America","volume":"62","author":"Barlam","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"11","key":"2022010419515758000_B28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1086\/501994","article-title":"Effectiveness of pharmacy policies designed to limit inappropriate vancomycin use: a population-based assessment","volume":"23","author":"Thomas","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"2022010419515758000_B29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1097\/INF.0b013e3182011d12","article-title":"Effectiveness of a guideline to reduce vancomycin use in the neonatal intensive care unit","volume":"30","author":"Chiu","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"2022010419515758000_B30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2018.36.30_suppl.290","article-title":"Reducing inappropriate empiric vancomycin use in neutropenic fever","volume":"36","author":"Kim","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022010419515758000_B31","first-page":"416","article-title":"Impact of an antibiotic stewardship program on the incidence of vancomycin-associated acute kidney injury in hospitalized children","volume":"24","author":"Hsu","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"12","key":"2022010419515758000_B32","doi-asserted-by":"crossref","first-page":"e173219","DOI":"10.1001\/jamapediatrics.2017.3219","article-title":"Association of acute kidney injury with concomitant vancomycin and piperacillin\/tazobactam treatment among hospitalized children","volume":"171","author":"Downes","year":"2017","journal-title":"JAMA Pediatr"},{"issue":"2","key":"2022010419515758000_B33","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1128\/AAC.04523-14","article-title":"Inappropriate continued empirical vancomycin use in a hospital with a high prevalence of methicillin-resistant Staphylococcus aureus [published correction appears in Antimicrob Agents Chemother. 2015;59(4):2478]","volume":"59","author":"Kim","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"2022010419515758000_B34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s12879-018-3081-1","article-title":"Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use: a quasi-experimental study in a region of high MRSA prevalence","volume":"18","author":"Choe","year":"2018","journal-title":"BMC Infect Dis"},{"issue":"4","key":"2022010419515758000_B35","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","article-title":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","volume":"26","author":"Dalton","year":"2020","journal-title":"Clin Microbiol Infect"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-009142\/1227629\/peds_2020009142.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2020-009142\/1227629\/peds_2020009142.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T19:52:28Z","timestamp":1641325948000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/148\/3\/e2020009142\/181084\/Empiric-Vancomycin-Reduction-in-a-Pediatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,9,1]]},"published-print":{"date-parts":[[2021,9,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2020-009142","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"e2020009142"}}